Bristol-myers Squibb Compnay

Piramanayagam Arunachalam

John V Duncia

Joseph B Santella

John T Hynes

Natesan Murugesan

Daniel S Gardner

Sreekantha Ratna Kumar

Satheesh Kesavan Nair

Hong Wu

Kandhasamy Sarkunam

Venkatram Reddy Paidi

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Rand R; and Rand Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Heteroaryl substituted nicotinamide compounds

Growing community of inventors

Bengaluru, India

Piramanayagam Arunachalam